【摘要】 目的检测血浆纤溶酶原激活剂抑制物-1(PAI-1),了解脑血栓患者PAI-1在治疗前后的变化。方法采用酶联免疫吸附双抗体夹心法检测35例脑血栓伴高血压患者(混合组)、33例单纯脑血栓患者(血栓组)、30例高血压患者(高血压组)和30例对照者(对照组)治疗前后以及30例健康人(健康组)血浆PAI-1水平。结果 PAI-1治疗前后分别为:混合组(185.6±31.6)ng/mL和(87.2±26.7)ng/mL,脑血栓组(163.5±30.8)ng/mL和(80.4±23.6)ng/mL,高血压组(96.2±26.3)ng/mL和(54.8±22.5)ng/mL,对照组(45.5±15.4)ng/mL和(40.2±12.8)ng/mL,健康组(25.2±8.3)ng/mL。前二组治疗前后血浆PAI-1差异有统计学意义(P<0.01),前三组与健康组比较,差异有统计学意义(P<0.01)。结论血浆PAI-1水平反映患者的凝血纤溶改变情况,与内皮细胞损伤密切相关,是观察脑血栓患者病情和疗效的有效实验指标。更多还原

【Abstract】 Objective To detect plasma plasminogen activator inhibitor-1(PAI-1) and to understand its change before and after treatment in the patients with cerebral thrombosis.Methods The double-antibody sandwich enzyme-linked immunosorbent assay was used to detect the plasma PAI-1 level in 35 cases of cerebral thrombosis complicating hypertension(mixed group),33 cases of simple cerebral thrombosis(thrombosis group),30 cases of hypertension(hypertension group) 30 control cases(control group) and other 30 healthy subjects as normal group.Results The plasma PAI-1 level before and after treatment were(185.6 ± 31.6)ng/mL and(87.2 ± 26.7)ng/mL in the mixed group,(163.5 ± 30.8) ng/mL and(80.4 ± 23.6)ng/mL in the cerebral thrombosis group,(96.2 ± 26.3) ng/mL and(54.8 ± 22.5)ng/mL in the hypertension group,(45.5±15.4)ng/mL and(40.2±12.8) ng/mL in the control group,respectively.The plasma PAI-1 level in the normal group was(25.2±8.3)ng/mL.The plasma PAI-1 level before and after treatment in the mixed group and the thrombosis group were significantly different(P<0.01).Comparing the former three groups with the normal group showed significantly different(P<0.01).Conclusion The plasma PAI-1 level reflects the changes of the patient′s coagulation and fibrinolysis status and is closely associated with endothelial cell injury,which can be used as an effective experimental index for observing the disease condition and treatment effects in the patients with cerebral thrombosis.更多还原